ASTCT Supports the FDA’s Approval of Earlier Use of CAR T-Cell Therapy for Multiple Myeloma
The Food and Drug Administration approves CAR T-Cell therapy Carvykti® as a second-line treatment and the CAR T-Cell therapy Abecma® as a third-line treatment for...